Lancashire and South Cumbria
Formulary
Formulary
10 Musculoskeletal and joint diseases
This chapter of the formulary is under continual development, please let the team know if you have any comments about the contents: mlcsu.lscformulary@nhs.net.
For more information about the formulary development process, please see: https://www.lancsmmg.nhs.uk/lancashire-and-south-cumbria-icb-formulary-development/
10-03-02 Capsaicin
| Capsaicin |
|
Formulary
|
Cream 0.025%, 0.075% Capsaicin cream is currently unavailable and this is likely to be the case until June 2026. |
|
| Capsaicin Qutenza® |
|
Formulary
|
Patch 179mg (8%) |
 LSCMMG: Qutenza (capsaicin) 179mg cutaneous patch NMR |
|
Links
- Bandolier review
- LSCMMG: Inflammatory Bowel Disease: High Cost Drugs Commissioning Pathway
- LSCMMG: Over the Counter Items that Should not be Routinely Prescribed in Primary Care Policy
- LSCMMG: Over the Counter Items that Should not be Routinely Prescribed in Primary Care Policy
- LSCMMG: Primary Care Constipation Guidelines
- LSCMMG: Qutenza (capsaicin) 179mg cutaneous patch NMR
- MHRA safety information on photosensivity reactions
- MHRA: Antiepileptic drugs in pregnancy: updated advice following comprehensive safety review
- NICE CG147: Diverticular disease: diagnosis and management
- NICE CG184 Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management
- NICE CG61: Irritable bowel syndrome in adults: diagnosis and management
- NICE NG1: Gastro-oesophageal reflux disease: recognition, diagnosis and management in children and young people